Ackman: Valeant A "Good" Roll Up Firm, Strategy Synergies

HFA Padded
Mark Melin
Published on
Updated on
CREW Herbalife Ltd. HLF Bill Ackman speaking

Bill Ackman was defending Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) today, upon which he is dependent on for a high stock price to fuel his hedge fund’s involvement in the Valeant / Allergan acquisition. The deal to purchase Allergan, Inc. (NYSE:AGN) is based in large part on the price of Valeant shares. In an interview with CNBC today, Ackman also talked about Valeant in terms of its value as a “roll up” company. Ackman teaming with Valeant to pressure Allergan As previously reported in ValueWalk, Ackman approached Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), a company engaged in purchasing other medical…

This content is exclusively for paying members of Hedge Fund Alpha

Log In

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

HFA Padded

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.